The Scientific Advisory Board
The Scientific Advisory Board provides managers with in-depth knowledge of the scientific foundations within the areas of medicine, clinical trials, practical use, products, companies and market trends. This is an invaluable asset for the investment managers.
Members have an extensive global network
The members also have an extensive network of medical experts in many different areas, both in Sweden and abroad. In total, hundreds of prominent researchers and experts at scientific institutions worldwide are included in this network.
The experts are consulted regularly
The portfolio managers and the Scientific Advisory Board hold four formal meetings each year with more in-depth discussions on topics selected by the managers. The work is led by its chair, Professor Sten Nilsson, with Henrik Rhenman as rapporteur.
Professor Sten Nilsson
Chairman / Professor emeritus of Oncology
Professor emeritus of Oncology and affiliated with Karolinska Institutet. Specialist in oncology and nuclear medicine. Former chairman of the Swedish Society of Oncology (SOF), the Swedish Society for Nuclear Medicine (SFNM) and the Swedish Society of Urological Oncology (SFUO). Sten has published more than 200 original papers in the scientific literature.
Professor Peter Arner
Professor of Medicine
Distinguished professor at Karolinska institutet. Expert physician and scientist in metabolism and endocrinology. Started Lipid Laboratory at Karolinska institutet performing research on metabolic diseases with focus on human adipose tissue. His current studies are on long-term effects of disturbed human fat cell function.
Professor Jan Lundberg
Professor of Neurotransmission
Previous professor of neurotransmission at the Pharmaceutical Faculty, Karolinska Institutet, and honorary doctor at the Pharmaceutical Faculty, Uppsala University, with more than 500 publications of scientific original articles. Recipient of the Fernström and Jahre awards. Previous head of research for AstraZeneca and Global R&D president for Eli Lilly. Has been involved in bringing 25 new medicines to regulatory approval and patients including several blockbusters. Cofounder of Aerocrine AB and currently a board member of 6 different biotechnology companies.
Fredrik Swahn
Doctor of Medicine
MD, PhD. Karolinska University Hospital Huddinge, Karolinska Comprehensive Cancer Center, Section for Upper GI. Disertation at Karolinska Institute 2012. Board member in the scientific research group (ANDRE) within the Scandinavian Association for Digestive Endoscopy (SADE), previous chairman of the Endoscopy Committee of Swedish Association of Gastroenterology, faculty member of the European Society of Gastrointestinal Endoscopy (ESGE). Since 23 years, clinically active as specialist in surgery, senior consultant with focus towards endoluminal surgery and besides that lecturing and organizing courses within the same topics.
Professor Tomas Olsson
Professor of Neurology
Professor of Neurology at Karolinska Institutet. Expert within the areas of auto-immune diseases and diseases of the nervous system. Has received several awards among those the Fernström Prize for young scientists. Has received a life time award for excellent MS research by the European committee for the research and treatment of multiple Sclerosis (ECTRIMS). Previously president for the International Society for Neuroimmunology (ISNI). Has published more than 600 articles, many of them in high impact journals. He now is a leader for a research group on neuro-immunological diseases at the center for molecular medicine, Karolinska Institutet.
Professor Ulf Eriksson
Professor of Vascular Biochemistry
Distinguished professor at Vetenskapsrådet (the Swedish Research Council) and at Karolinska Institutet. Expert in vascular biology, especially regarding the role of blood vessels in metabolism, diabetes and stroke. Member of the Nobel Committee at Karolinska Institutet and was its chairman in 2022. Ulf holds several faculty assignments at Karolinska Institutet and has received the Swedish Medical Society's Jubilee Award and The Svedbergs Award. He has also published more than 175 research articles, many in leading international journals.
Dr. Göran Ando
Göran Ando is a medical doctor and has more than 40 years of leadership in the biotech and pharmaceutical industry, including 13 years as vice chairman and chairman of Novo Nordisk AS. He joined the industry with Pfizer and has subsequently spent most time with Glaxo (now GSK) as medical director advancing to development director and finally R&D Director. In 1995 he joined Pharmacia as Executive Vice President and Deputy CEO heading R&D, manufacturing, IT, BD and M&A. When Pharmacia was sold in 2003, he was appointed CEO of Celltech Group in the UK until UCB acquired the company. Göran is a qualified medical doctor and a founding fellow of the American College of Rheumatology. He was awarded an honorary doctor degree by Karolinska Institute in 2002.